Please assess the completion status of the following clinical trial:

Trial Title: Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of exocrine pancreas~* Metastatic disease~* Documented disease progression after treatment with 1 line of prior gemcitabine-based regimen~* Karnofsky performance status equal or more than 70~Exclusion Criteria:~* With active CNS metastases~* With clinically significant gastrointestinal disorder (e.g., bleeding, inflammation, occlusion, or diarrhea \> grade 1)~* Major surgery or radiotherapy within 4 weeks~* Prior participation in any investigational drug study within 4 weeks~* With prior irinotecan treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEP02 (Type: EXPERIMENTAL): Liposome Irinotecan

Based on this trial design, predict the completion outcome and termination type (if applicable).